Pulse Biosciences
PLSE
49.09
-0.66
-1.33%
Pulse Biosciences
US · PLSE
#2388 by market cap
Listed 2016
49.09
-0.66
-1.33%
Live - 5344 symbols - heartbeat 473s ago
· 2026-10-08 07:21
Pre-market
50.41
+2.69%
After-hours
49.09
0.00%
- Market cap
- 3.50B
- P/E (TTM)i
- -41.96
- P/Bi
- 35.19
- EPSi
- -1.08
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on PLSE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 142.73, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
- Gross margin
- -54.00%
- Operating margin
- -21,982.57%
- Net margin
- -20,794.57%
Key ratios & quality
- Altman Z-Scorei
- 142.73
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.42M | 700.00K | 0 | 0 | 350.00K |
| Gross profit | -- | 0 | 0 | -550.00K | -11.24M | -- | 0 | -189.00K |
| Selling & admin expenses | 20.05M | 22.99M | 23.52M | 33.82M | 25.97M | 15.78M | 23.92M | 32.03M |
| Research & development | 17.25M | 24.96M | 26.44M | 28.64M | 20.84M | 27.80M | 32.34M | 44.72M |
| Operating profit | -37.96M | -47.95M | -49.97M | -63.01M | -58.06M | -43.57M | -56.26M | -76.94M |
| Pretax profit | -37.55M | -46.97M | -49.85M | -63.66M | -58.51M | -42.21M | -53.59M | -72.78M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | -- | -- |
| Net profit | -37.55M | -46.97M | -49.85M | -63.66M | -58.51M | -42.21M | -53.59M | -72.78M |
| Basic EPS | -2 | -2 | -2 | -2 | -2 | -1 | -1 | -1 |
| Diluted EPS | -2.16 | -2.22 | -2.10 | -2.24 | -1.69 | -0.85 | -0.92 | -1.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 86.00K | 264.00K | 401.00K | 434.00K |
| Gross profit | 0 | 0 | -193.00K | 4.00K | 31.00K | 161.00K |
| Selling & admin expenses | 7.73M | 8.19M | 8.78M | 7.33M | 6.59M | 8.46M |
| Research & development | 10.31M | 12.09M | 11.39M | 10.93M | 12.59M | 16.98M |
| Operating profit | -18.04M | -20.28M | -20.37M | -18.25M | -19.15M | -25.27M |
| Pretax profit | -16.80M | -19.17M | -19.39M | -17.43M | -18.58M | -24.66M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -16.80M | -19.17M | -19.39M | -17.43M | -18.58M | -24.66M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.25 | -0.28 | -0.29 | -0.26 | -0.27 | -0.36 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 60.36M | 26.40M | 22.34M | 36.63M | 62.15M | 45.33M | 119.45M | 83.42M |
| Cash & ST investments | 59.58M | 25.40M | 20.48M | 28.61M | 61.14M | 44.37M | 118.04M | 80.74M |
| Inventory | -- | -- | 0 | 5.82M | -- | -- | 0 | 136.00K |
| Total assets | 70.64M | 41.92M | 41.29M | 54.25M | 77.88M | 59.15M | 132.46M | 94.54M |
| Total current liabilities | 3.11M | 4.46M | 7.59M | 8.52M | 5.98M | 6.71M | 10.06M | 7.92M |
| Short-term debt | -- | -- | 542.00K | 1.21M | 1.81M | 1.06M | 1.36M | 1.57M |
| Long-term debt | -- | -- | -- | -- | 65.00M | -- | -- | -- |
| Total liabilities | 4,306,000.00 | 11,178,000.00 | 18,399,000.00 | 18,559,000.00 | 80,125,000.00 | 14,794,000.00 | 17,598,000.00 | 13,883,000.00 |
| Total equity | 66.33M | 30.74M | 22.89M | 35.69M | -2.25M | 44.36M | 114.86M | 80.66M |
| Retained earnings | -75.72M | -122.69M | -172.54M | -236.20M | -294.71M | -336.92M | -390.50M | -463.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 120.91M | 108.16M | 97.16M | 83.42M | 71.13M | 105.70M |
| Cash & ST investments | 119.28M | 106.35M | 95.21M | 80.74M | 68.32M | 101.62M |
| Inventory | 30.00K | 51.00K | 57.00K | 136.00K | 206.00K | 236.00K |
| Total assets | 133.38M | 120.25M | 108.77M | 94.54M | 81.62M | 115.56M |
| Total current liabilities | 7.76M | 8.98M | 9.70M | 7.92M | 9.80M | 10.98M |
| Short-term debt | 1.41M | 1.46M | 1.52M | 1.57M | 1.63M | 1.69M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 14,931,000.00 | 15,764,000.00 | 16,071,000.00 | 13,883,000.00 | 15,324,000.00 | 16,064,000.00 |
| Total equity | 118.45M | 104.49M | 92.69M | 80.66M | 66.30M | 99.50M |
| Retained earnings | -407.30M | -426.46M | -445.85M | -463.28M | -481.86M | -506.52M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.90M | -34.19M | -35.37M | -54.10M | -47.01M | -33.04M | -36.34M | -54.12M |
| Depreciation & amortization | 1.31M | 1.16M | 1.10M | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| Free cash flow | -24.17M | -34.79M | -35.81M | -54.53M | -47.41M | -33.16M | -36.47M | -54.46M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 44.79M | 0 | 29.43M | 56.70M | 14.86M | 0 | 59.65M | 0 |
| Ending cash balance | 51.10M | 6.90M | 12.46M | 28.61M | 61.14M | 44.37M | 118.04M | 80.74M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.52M | -12.81M | -13.04M | -14.76M | -14.60M | -18.71M |
| Depreciation & amortization | 283.00K | 273.00K | 256.00K | 259.00K | 255.00K | 254.00K |
| Free cash flow | -13.57M | -12.93M | -13.10M | -14.86M | -14.63M | -18.80M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 352.00K | -- | -- | 0 | 465.00K | 45.93M |
| Ending cash balance | 119.28M | 106.35M | 95.21M | 80.74M | 68.32M | 101.62M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -66.85 | -96.78 | -185.90 | -217.33 | -349.89 | -200.47 | -67.31 | -74.45 |
| ROA %i | -62.34 | -83.46 | -119.82 | -133.26 | -88.56 | -61.61 | -55.93 | -64.12 |
| ROIC %i | -67.64 | -86.79 | -138.32 | -156.82 | -96.98 | -66.36 | -60.46 | -72.65 |
| 5-year avg ROE %i | -- | -60.62 | -94.02 | -127.72 | -183.35 | -210.07 | -204.18 | -181.89 |
| EBIT margin %i | -- | -- | -- | -4,443.86 | -8,293.86 | -- | -- | -21,982.57 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.42 | 5.92 | 2.95 | 4.30 | 10.39 | 6.76 | 11.88 | 10.53 |
| Quick ratioi | 19.17 | 5.70 | 2.70 | 3.37 | 10.22 | 6.61 | 11.74 | 10.22 |
| Debt / assetsi | -- | 16.03 | 27.50 | 20.74 | 97.53 | 15.46 | 6.72 | 7.97 |
| LT debt / equityi | -- | 21.86 | 47.24 | 28.13 | -- | 18.23 | 6.57 | 7.39 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | -- | -- | 0.00 | -- | -20.63 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -77.86 | -103.50 | -86.99 | -74.45 | -80.72 | -78.49 |
| ROA %i | -66.00 | -84.68 | -74.06 | -64.12 | -69.36 | -67.90 |
| ROIC %i | -69.96 | -91.72 | -79.47 | -72.65 | -77.93 | -75.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -91,798.84 | -21,982.57 | -10,392.14 | -7,007.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.58 | 12.05 | 10.02 | 10.53 | 7.26 | 9.63 |
| Quick ratioi | 15.37 | 11.85 | 9.82 | 10.22 | 6.99 | 9.27 |
| Debt / assetsi | 6.43 | 6.86 | 7.25 | 7.97 | 8.77 | 5.86 |
| LT debt / equityi | 6.05 | 6.49 | 6.87 | 7.39 | 8.34 | 5.11 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenues100.00%
Quote time 2026-10-08 07:21:47 · For reference only, not investment advice and not tailored to your situation.